A Novel Treatment Option for Autism Spectrum Disorder
INDICATION
Autism Spectrum Disorder (ASD)
The autism community urgently needs better therapeutic options. Currently only two drugs are approved to address this condition, and both come with frequent adverse side effects.
Drug Candidate - AJA001 DeFloria™
DEFLORIA is a joint venture between Ajna BioSciences, Charlotte’s Web, and BAT dedicated to developing the first FDA-Approved, full spectrum botanical hemp extract specifically tailored to alleviate the symptoms of Autism Spectrum Disorder.
A Full Spectrum CBD Extract
DeFloria is a collaborative venture born from the passion and expertise of Charlotte’s Web and AJNA BioSciences. It’s the natural next step after more than a decade of hard work and innovation with Charlotte’s Web—the trusted name behind the hemp extract that helped shape an entire industry. Now, partnering with AJNA, a true leader in botanical drug development, we’re poised to advance AJA001 through clinical trials, addressing significant unmet needs in the autism community and beyond.
The name DeFloria encapsulates our core ethos: “De,” meaning "originating from," and “Floria,” meaning "flower," reflecting our commitment to harnessing nature’s therapeutic potential through advanced, scientifically validated medicine. AJA001 is derived from flowers, bridging nature with lab standardization for countless lives affected by ASD.
-
Leveraging Charlotte’s Web's premium proprietary hemp extracts and Ajna’s proven drug development expertise, DEFLORIA is poised to fulfill its mission with excellence and innovation.
-
Harnessing the therapeutic potential of CBD delivers healing benefits without the psychoactive implications commonly linked to cannabis. This serves as the cornerstone for expansive R&D and future applications.
-
Renowned entrepreneurs with a successful track record in the CBD wellness sector, guided by top-tier thought leaders including Orrin Devinsky, MD., world-renowned pediatric neurologist and lead principal investigator for Epidiolex™, the only FDA-approved CBD drug.
-
Upon FDA approval, DEFLORIA gains first mover advantage fortified by patent protection. Initiated 18 months ago, DEFLORIA’s program is poised to deliver the world’s first oral-systemic botanical drug.
JOINT VENTURE HIGHLIGHTS
A recent study indicates that all three of these component molecules found in AJA001 are likely important in treating ASD in the general population.
ENTOURAGE EFFECT
DEVELOPMENT TIMELINE
LEADERSHIP TEAM & BOARD
-
Jared Stanley
Chief Executive Officer - Co-founder & Board member of Charlotte’s Web with 15+ years experience in cannabis operations.
-
Orrin Devinsky, MD
Chief Medical Advisor - Ajna BioSciences, Director Comprehensive Epilepsy Center at NYU Langone. Formerly lead principal investigator for Epidiolex™.
-
Ryan Lanier, PhD
Chief Scientific Advisor - 20+ years researching CNS compounds including cannabinoids & psychedelics. Expert in pharmaceutical product development from IND-enabling studies through Phase III clinical trials.
-
Marcel Bonn-Miller
Board Member - Chief Scientific Officer - Charlotte’s Web, 20+ years of cannabinoid drug development expertise, including Zynerba Pharmaceuticals and Canopy Growth Corporation.
-
Joel Stanley
Board Chairman - Co-founder Ajna BioSciences Former CEO & Board Chairman of Charlotte’s Web.
-
Donna Gutterman, PharmD, MBA
President at Onesta, Inc., 35+ years pharmaceutical industry experience (GSK) in developing, launching and commercialization of medicines in CNS therapeutic area.
-
Bob Judge
Board Member - 30+ years as CFO and consultant to numerous industries including CBD. Senior manager with KPMG on public and private entities. VP Finance - Ajna Biosciences
-
Stephen Rogers
DEFLORIA Board Member, Senior Vice President, General Counsel, and Corporate Secretary at Charlotte’s Web
Join us in leading change and creating hope for millions.
Our groundbreaking work has led us to the cusp of a medical breakthrough, and we invite you to be part of this revolutionary journey.
